LORAZEPAM tablet

Nchi: Marekani

Lugha: Kiingereza

Chanzo: NLM (National Library of Medicine)

Viambatanisho vya kazi:

Lorazepam (UNII: O26FZP769L) (Lorazepam - UNII:O26FZP769L)

Inapatikana kutoka:

McKesson Packaging Services Business Unit of McKesson Corporation

INN (Jina la Kimataifa):

Lorazepam

Tungo:

Lorazepam 0.5 mg

Dawa ya aina:

PRESCRIPTION DRUG

Idhini hali ya:

Abbreviated New Drug Application

Tabia za bidhaa

LORAZEPAM- LORAZEPAM TABLET
MCKESSON PACKAGING SERVICES BUSINESS UNIT OF MCKESSON CORPORATION
----------
LORAZEPAM TABLETS, USP
DESCRIPTION
Lorazepam, an antianxiety agent, has the chemical formula,
7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-
hydroxy-2_H_-1,4-benzodiazepin-2-one:
C H CL
N O M.W. 321.16
It is a nearly white powder almost insoluble in water.
Each lorazepam tablet, to be taken orally, contains 0.5 mg, 1 mg, or 2
mg of lorazepam. The inactive
ingredients present are: lactose, hypromellose USP, specially
denatured alcohol 3A, pregelatinized
starch NF, and magnesium stearate NF.
CLINICAL PHARMACOLOGY
Studies in healthy volunteers show that in single high doses,
lorazepam has a tranquilizing action on the
central nervous system with no appreciable effect on the respiratory
or cardiovascular systems.
Lorazepam is readily absorbed with an absolute bioavailability of 90
percent. Peak concentrations in
plasma occur approximately 2 hours following administration. The peak
plasma level of lorazepam from
a 2 mg dose is approximately 20 ng/mL.
The mean half-life of unconjugated lorazepam in human plasma is about
12 hours and for its major
metabolite, lorazepam glucuronide, about 18 hours. At clinically
relevant concentrations, lorazepam is
approximately 85% bound to plasma proteins. Lorazepam is rapidly
conjugated at its 3-hydroxy group
into lorazepam glucuronide which is then excreted in the urine.
Lorazepam glucuronide has no
demonstrable CNS activity in animals.
The plasma levels of lorazepam are proportional to the dose given.
There is no evidence of
accumulation of lorazepam on administration up to six months.
Studies comparing young and elderly subjects have shown that advancing
age does not have a significant
effect on the pharmacokinetics of lorazepam. However, in one study
involving single intravenous doses
of 1.5 to 3 mg of lorazepam injection, mean total body clearance of
lorazepam decreased by 20% in 15
elderly subjects of 60 to 84 years of age compared to that in 15
younger subjects of 19 to 38 year